ORLANDO, FL • 2019-12-09

BostonGene and Weill Cornell Medicine Reveal Results from Cancer Microenvironment Study

5 min to read

BostonGene Corporation (BostonGene), a Boston-based biomedical software company, presented results of its recent cancer microenvironment study during the 61st American Society of Hematology Annual Meeting and Exposition held
ORLANDO, FL , December 9, 2019 - BostonGene Corporation (BostonGene), a Boston-based biomedical software company, presented results of its recent cancer microenvironment study during the 61st American Society of Hematology Annual Meeting and Exposition held on December 7-10, 2019. The research study examined the role of the tumor microenvironment of Diffuse Large B-Cell Lymphoma (DLBCL).

The study, conducted as part of BostonGene’s collaboration with Weill Cornell Medicine, combined whole exome and transcriptome analyses from an integrated cohort of 3,026 DLBCL patients. The cohort includes publically available data as well as prospective patients.

The study revealed that a new classification based on the tumor microenvironment is associated with clinical outcomes independently of existing molecular subtypes. Computationally predicted results demonstrated a strong correlation with response therapy obtained in murine DLBCL models for subtypes based on stromal, immune and malignant composition.

“Improving treatment outcomes for individual DLBCL patients by integrated analysis of large-scale next-generation sequencing (NGS) data including somatic variants and gene expression changes in the tumor and the tumor microenvironment is our top priority,” said Leandro Cerchietti, M.D., Associate Professor of Medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. “These promising findings bring us one step closer to achieving that goal.”

“We are proud to collaborate with Weill Cornell Medicine to provide advanced computational analytics for the integration of big data sets generated for each patient,” said Andrew Feinberg, President and CEO of BostonGene. “We look forward to continuing our collaboration to further identify the best treatment options for cancer patients.”

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com